UBS Group’s Agilon Health AGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-40
Closed -$12.6K 9241
2023
Q4
$12.6K Hold
40
﹤0.01% 7343
2023
Q3
$17.8K Hold
40
﹤0.01% 6866
2023
Q2
$17.3K Hold
40
﹤0.01% 6939
2023
Q1
$23.8K Buy
+40
New +$22.4K ﹤0.01% 6959

Other funds holding AGL

UBS Group's AGL Position: Q2 2026 in Review

UBS Group reduced its Agilon Health (AGL) stake by 12% in Q2 2026, selling an estimated $461K and leaving 51,084 shares worth $5.48M. The position accounts for ﹤0.01% of the portfolio, ranked #4079.

UBS Group first reported a position in AGL in Q2 2021 and has held it in 21 quarters since. The position peaked at $6.52M in Q1 2025. 179 funds tracked by Wall St. Rank hold AGL as of Q2 2026.

  • UBS Group held 51,084 shares of Agilon Health worth $5.48M as of Q2 2026.
  • UBS Group sold 7,036 Agilon Health shares in Q2 2026, an estimated $461K.
  • Agilon Health made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4079 holding.
  • UBS Group first reported a position in Agilon Health in Q2 2021 and has held it in 21 quarters since.
  • UBS Group's Agilon Health position peaked at $6.52M in Q1 2025.
  • 179 funds tracked by Wall St. Rank held Agilon Health as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.